– USA, MA – Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI), a clinical-stage biopharmaceutical today announced the addition of Dr. Jon Wigginton (M.D.) to its Board of Directors.
“Jon is a well-respected physician-scientist and drug development expert. With his diverse background, he has driven numerous clinical stage immuno-oncology development portfolios. We are thrilled to strengthen Checkmate’s Board by leveraging Jon’s broad experience across academia, government and the biopharmaceutical industry, as well as his lifelong career dedication to improving the lives of patients with cancer,” said Interim CEO, Alan Fuhrman.
About Dr. Jon Wigginton
Dr. Wigginton has over 25 years of experience in clinical oncology and currently serves as Senior Advisor and Chairman of the SAB at Cullinan Oncology, Inc. Dr. Wigginton previously served as CMO at Cullinan Oncology, Inc., and an advisor for MPM Capital. Prior, he was CMO at MacroGenics, where he led the company’s evolution of a fully-integrated clinical-stage cancer immunotherapy organization. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head in Immuno-Oncology for Early Clinical Research and as Executive Medical Director and Group Medical Director of Discovery Medicine-Clinical Oncology, where he led the early clinical development of the BMS Immuno-Oncology portfolio. Before that, Dr. Wigginton was Director, Clinical Oncology at Merck Research Laboratories. In addition, he previously served as President of the Society for Immunotherapy of Cancer. Earlier in his career, Dr. Wigginton worked at the National Cancer Institute for over 14 years and was Head of the Investigational Biologics Section in the Center for Cancer Research. Dr. Wigginton is currently a member of the Board of Directors of Sutro Biopharma.
“I am excited to join the highly experienced Board at Checkmate,” said Dr. Wigginton. “Cancer immunotherapy has revolutionized the treatment of patients with many solid tumors and hematologic malignancies. Vidutolimod, a unique CpG-A DNA TLR9 agonist, may provide a new approach to drive innate immunity and has demonstrated encouraging evidence of antitumor activity as a monotherapy and in combination with checkpoint inhibitors. I look forward to working with my colleagues on Checkmate’s Board and management team to help advance this new approach for the treatment of patients with cancer.”
He earned his M.D. and B.S in biology from the University of Michigan.
About Checkmate
Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like receptor 9 agonist, delivered as a biologic virus-like particle utilizing a CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies.
For more information: https://checkmatepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
